All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Celltrion Healthcare Inc. planted the oncology flag in biosimilars with the European Commission's approval of Truxima, a biosimilar to Rituxan (rituximab, Roche Holding AG/Biogen Inc.), and the compound will provide estimated health care savings across the 28 countries of the EU of about €570 million (US$602 million) over a three-year period.